Humanized Monoclonal Antibody

About Vitalex Biosciences

Vitalex Biosciences is a private, pre-revenue biotech focused on innovative solutions for serious fungal and bacterial infections. Its core assets include a dual-antigen vaccine targeting Candida species and Gram-negative bacteria, and a monoclonal antibody for mucormycosis, both supported by over $10 million in non-dilutive NIH funding. The company leverages the deep scientific expertise of its founder, Dr. Ashraf Ibrahim, a recognized leader in fungal pathogenesis, and a small team with experience in research, manufacturing, and corporate law.

Therapeutic Areas

Other Mucormycosis Drugs